Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Special Drug Use Surveillance of Ceprotin (TAK-662) in Congenital Protein C Deficiency
jRCT2031240322Recruiting
- Sponsor
- Takeda
- Start
- Sep 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of Protein C concentrate in congenital protein C deficiency, sponsored by Takeda. Primary endpoint: Treatment-emergent adverse events (TEAEs). Started Sep 2024; status: recruiting.
02
Drugs
Protein C concentrate
03
Conditions
congenital protein C deficiency
Beyond the preview
Go deeper on jRCT2031240322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240322.